2024
Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorDisease ProgressionFemaleHumansMaleMelanomaMiddle AgedReceptor, Melanocortin, Type 1Skin NeoplasmsConceptsMC1R expressionMelanoma progressionAssociated with shorter survivalStages of melanoma progressionCases of benign neviChronic sun exposureMarkers of progressionHuman melanoma tissuesBreslow thicknessMelanocortin-1Metastatic melanomaOverall survivalPrimary melanomaMetastatic tumorsMelanoma cohortReceptor expressionPredictive biomarkersAggressive melanomaPrimary lesionTissue microarrayShorter survivalMale sexQuantitative immunofluorescenceBenign neviClinical trialsDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.Peer-Reviewed Original ResearchMeSH KeywordsActinsBiomarkers, TumorCTLA-4 AntigenHumansMelanomaProgrammed Cell Death 1 ReceptorProteomicsTumor MicroenvironmentConceptsCTLA-4 expression levelsCancer-associated fibroblastsAssociated with worse survivalExpression of immune checkpointsLAG-3 expressionDesmoplastic melanomaLymphoid aggregatesCTLA-4PD-1Immune checkpointsIntratumoral leukocytesLAG-3Tumor compartmentsWorse survivalCD20+B cellsIncreased expression of immune checkpointsProgrammed cell death protein 1Macrophage/monocyte markerSentinel lymph node positivityCell death protein 1Associated with poor prognosisLymph node positivityDense fibrous stromaPotential prognostic significanceCore of tumors
2011
Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas
Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology 2011, 24: 1237-1247. PMID: 21552209, PMCID: PMC3155013, DOI: 10.1038/modpathol.2011.74.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaE-cadherin expressionPancreatic adenocarcinomaDuctal adenocarcinomaIndependent predictorsPoor outcomeCox proportional hazards regression modelingProportional hazards regression modelingPancreatic cancer outcomesWorse median survivalResectable pancreatic adenocarcinomaMinority of patientsKaplan-Meier analysisE-cadherin statusMedian survivalSurgical resectionWorse prognosisCancer outcomesSubgroup analysisPathological factorsPatient outcomesCell adhesion moleculeMortality riskTissue microarrayPartial lossTyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer
Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, Anders RA, Illei PB, Van Eyk JE, Maitra A, Laheru D, Jaffee EM. Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer. PLOS ONE 2011, 6: e19390. PMID: 21572519, PMCID: PMC3084841, DOI: 10.1371/journal.pone.0019390.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnnexin A2Antibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorBlotting, WesternCancer VaccinesCell Line, TumorCell MembraneCell MovementDisease-Free SurvivalEpithelial-Mesenchymal TransitionFemaleHumansLiverMiceMice, Inbred C57BLNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, ExperimentalPancreatic NeoplasmsPhosphorylationRNA InterferenceTumor Cells, CulturedTyrosineConceptsPancreatic ductal adenocarcinomaAnti-ANXA2 antibodiesPDA metastasisEpithelial-mesenchymal transitionAnnexin A2PDA cellsPost-treatment seraProlongs mouse survivalHigh metastatic potentialCalcium-dependent phospholipid-binding proteinMouse survivalPancreatic cancerDuctal adenocarcinomaEffective therapyProlonged survivalNovel molecular pathwaysANXA2 expressionSerum inhibitsMetastasisPhospholipid-binding proteinEMT processMetastatic potentialAntibody inhibitsPDA developmentNew targets